Harnessing the power of Imaging Phenomics

At Median, we’re transforming the science of medical imaging. By harnessing the power of Imaging Phenomics we can improve current treatment, enhance diagnosis and accelerate development of next generation therapies, helping make a healthier world for millions.

The fight against disease is a joint effort

While our expertise and resources are unique, we don’t work alone. The fight against disease is a joint effort and the spirit of cooperation is found in everything we do. Whether working in clinical trials or patient care and treatment, we share the same single-minded goal. To defeat the diseases that still touch so many lives.

Pushing the boundaries of imaging technology

At Median we’re determined to push the boundaries of what imaging technology can achieve, to help develop next generation treatments with the potential to save or improve the lives of millions.

CEO’s message


Fredrik Brag talks about how we’re looking to change the game. To transform the landscape in which we work and create a new world of possibilities for biopharma companies and healthcare professionals alike.

Read more

START & Median

START & Median Technologies Partnership on imaging in oncology clinical trials. Dr. Tony Tolcher talks about the importance of our partnership for imaging in oncology clinical trials. Watch the 2 minute video to learn more.

Watch

News

25 April 2017

Median Technologies is awarded the 2017 Tech 40 Label and joins EnterNext Tech 40 Index.

Tech 40 Index includes top-performing Tech companies listed on the Euronext. The Tech 40 Label denotes Median Technologies as a high potential innovative company among Tech companies, and will enhance its visibility among international investors.

12 April 2017

Median Technologies reports Full Year 2016 Financial Results

+ 64% of revenues and €41.8m in net cash as of Dec. 31, 2016. 2016 was a strategic turning point year, with major operational and business development investments made in anticipation of Median’s growth: Executive team strengthening through major company appointments with significant headcount increases in the US and in France. Development of iBiopsy®, the Median imaging phenotyping platform, is driving the R&D effort and is central in the company positioning strategy for upcoming years.

6 April 2017

Median Technologies and inVentiv Health Announce Strategic Alliance to Provide Best-in-Class Medical Image Analysis and Management Services for Clinical Trials

Median Technologies, the Imaging Phenomics Company™, and inVentiv Health, a leading biopharmaceutical professional services company, today announced a strategic alliance to offer biopharmaceutical clients with best-in-class medical image analysis and management services for early to late stage oncology clinical trials. The alliance will provide inVentiv clients with the most advanced imaging biomarkers, at a time when 73 percent of cancer compounds in clinical trials involve biomarkers in their research and development design.

28 February 2017

Median Technologies to present at Cowen and Company 37th Annual Health Care Conference

Fredrik Brag, Median’s Chief Executive Officer, will provide an overview of the Company and its strategic objectives at the Cowen and Company 37th Annual Health Care Conference. The presentation will take place on Tuesday, March 7th at 08:40 am EST at the Marriott Copley Place in Boston, Massachusetts, USA.

14 February 2017

Median Technologies to attend the Annual Meeting of the Asian Pacific Association for the Study of the Liver, February 15-19, 2017, Shanghai, China

Median Technologies will showcase its iBiopsy™ platform for liver diseases at the FURUI/Echosens booth #116-117 and present during the FURUI/Echosens satellite symposium on February 16, from 18:00 to 19:30. The joint participation and presentation result from FURUI’s investment into Median Technologies completed in December, 2016.

1/5

Opinion

26 April 2017
Making Volumetric Tumor Measurements:  The Nuts and Bolts

Making Volumetric Tumor Measurements: The Nuts and Bolts

Going Beyond RECIST – Part 3 Making Volumetric Tumor Measurements:  The Nuts and Bolts  [Part 3 of our 3 Part series on Going…

13 April 2017
Why It’s Important to Add Volume Data to a Clinical Study

Why It’s Important to Add Volume Data to a Clinical Study

Going Beyond RECIST – Part 2 Why It’s Important to Add Volume Data to a Clinical Study [Part 2 of our 3 Part…

5 April 2017
Are Volumetric Assessments a True Reflection of Drug Response?

Are Volumetric Assessments a True Reflection of Drug Response?

Going Beyond RECIST – Part 1 Are Volumetric Assessments a True Reflection of Drug Response? [Part 1 of our 3 Part series on…

9 March 2017
Released today in The Lancet Oncology: New iRECIST Guidelines for response criteria for use in trials testing immunotherapeutics – soon to be integrated within Median’s imaging Lesion Management Solution (LMS) software.

Released today in The Lancet Oncology: New iRECIST Guidelines for response criteria for use in trials testing immunotherapeutics – soon to be integrated within Median’s imaging Lesion Management Solution (LMS) software.

Immunotherapies display novel response patterns that affect the design of imaging based studies and the subsequent evaluation of imaging data. Applying traditional chemotherapy-based…

1/4
Imaging for patient care

Identifying treatments that work

Imaging biomarkers provide a unique insight into treatment progress at every stage of a disease. In cancer for instance, comprehensive quantitative information plays an invaluable role in defining, tracking and measuring treatment outcomes. Providing clear evidence of what works and what doesn’t.

Read more

Imaging for clinical trials

Advancing treatments of the future

Working with biopharmaceutical companies, and leading medical centers around the world, the team at Median enable researchers to identify disease fingerprints from medical images. We’re helping paving the way for new personalized and innovative medicines, more accurate and predictable diagnoses and better treatments

Read more

Ibiopsy®

Powering the phenomics revolution

We’re changing the game; transforming the landscape. We’re capturing the power of big data and unique biomarker imaging technology to create a new world of possibilities for biopharma and healthcare professionals alike. Our iBiopsy® platform opens up the field of phenomics, driving the science of precision medicine.

Read more

Investors

Delivering value

Our technology and expertise is creating a new world of possibilities for biopharmaceutical and healthcare professionals around the world. By successfully helping improve the lives of millions, we are also delivering value for our investors and partners.

Read more

Share Price

13.00€ -0.18 (-1.38%) MNEMO: AMLDT
Get in touch

europe

Median Technologies
Les Deux Arcs, Bât B
1800, route des Crêtes
06560 Valbonne
France

Get in touch

Get in touch





Jobs at Median

United States

Legal address
Median Technologies Inc
C/O Pramex International
1251 Avenue of the Americas
3rd Floor
New York NY 10020

US offices

Median Technologies Inc
300 TradeCenter
Suite 5610
Woburn MA 01801

Cookies help us deliver our services. By using our services, you agree to our use of cookies.